BioLight Life Sciences Ltd. (TLV:BOLT)
Israel · Delayed Price · Currency is ILS · Price in ILA 383.00
-8.10 (-2.07%)
At close: Jan 30, 2026
BioLight Life Sciences Revenue
BioLight Life Sciences had revenue of 21.00K ILS in the twelve months ending September 30, 2025, down -91.25% year-over-year. In the year 2024, BioLight Life Sciences had annual revenue of 219.00K with 85.59% growth.
Revenue (ttm)
21.00K
Revenue Growth
-91.25%
P/S Ratio
1,650.11
Revenue / Employee
5.25K
Employees
4
Market Cap
34.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 219.00K | 101.00K | 85.59% |
| Dec 31, 2023 | 118.00K | 55.00K | 87.30% |
| Dec 31, 2022 | 63.00K | 60.00K | 2,000.00% |
| Dec 31, 2021 | 3.00K | -28.00K | -90.32% |
| Dec 31, 2020 | 31.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 42.17M |
| Evogene | 26.54M |
| XTL Biopharmaceuticals | 3.26M |
| Can-Fite BioPharma | 1.89M |
| Clal Biotechnology Industries | 91.00K |
| Geffen Residence & Renewal | 84.00K |